Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Micromet Presents Update At ASCO 2009 On A Phase 1b Combination Study Of Adecatumumab And Docetaxel
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented data from a clinical trial investigating its anti-EpCAM human antibody adecatumumab (MT201) in combination with the chemotherapeutic docetaxel in patients with metastatic breast cancer (MBC) at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida, USA(1).

Proteomics: Finding The Key Ingredients Of Disease
The winner of the chilli cook-off, usually has a key secret ingredient, which is hard to identify. Similarly, many diseases have crucial proteins, which change the dynamics of cells from benign to deadly. New findings from an international collaboration, involving McGill University, the Research Institute of the McGill University Health Centre (MUHC) and the Human Proteome Organisation (HUPO) just made identifying these changes one step easier. Their findings published in Nature Methods, show how to improve protein analysis to tease out relevant potential disease-causing molecules.
News of the day
Small Business Owners Deliver Mixed Messages To Capitol Hill
As more specific legislative language emerges on health care, "small business organizations are encouraging members to make their views known through e-mails, letters, phone calls and personal visits" to members of Congress, but "the message is a decidedly mixed one," Kaiser Health News reports. "Small business, a powerful constituency in every congressional district, no longer speaks with one voice on health care. Many of the bigger and more powerful groups that represent small businesses, including the National Federation of Independent Business (NFIB) and the U.S. Chamber of Commerce, have long been allied with Republicans and are lobbying hard against the public option and the employer mandate." But newer, less conservative groups, including the Main Street Alliance, are advocating for those same hot button issues.
Mental Health

Postoperative PSA And PSA Velocity Identify Presence Of Prostate Cancer After Various Surgical Interventions For Benign Prostatic Hyperplasia

UroToday.com - Men undergoing surgical interventions for BPH are still at risk for subsequent development of prostate cancer (CaP) due to residual tissue. It is suggested that PSA decreases approximately 0.1-0.3ng/ml for every 1g of prostate tissue removed. In the online edition of Urology, Dr. Brian Helfand and associates determined the PSA values and PSAV in patients who had undergone TURP, holmium laser resection of the prostate (HoLRP), or open prostatectomy (OP) for treatment of BPH and compare these values in patients with histologic BPH only with the values in those with incidentally found CaP. The study was a retrospective review of 525 patients who had undergone one of these three procedures from 1992 to 2007. If incidental CaP was histologically found, patients were excluded if they underwent additional therapy as it would affect the PSA values. Only CaP patients who underwent watchful waiting were thus included. Patients on 5-alpha reductase inhibitors had their PSA values doubled and PSAV was calculated for all participants. A total of 444 men were included in the analysis, 73.7% of whom had undergone TURP, 11.6% HoLRP and 14.7% OP. The average PSA value for all patients who underwent TURP, HoLRP, and OP was 4.3, 3.2, and 10.5ng/ml, respectively. Every patient in the OP group underwent at least one prostate biopsy compared with 20% of men in the TURP group and 12% of men in the HoLRP group. Incidental CaP was diagnosed in 8.7%, 1.9%, and 17.6% of the TURP, HoLRP, and OP patients, respectively. Additional treatment was given to 17 men in the TURP group and 4 in the OP group for their CaP. No significant differences were found between groups with regard to the mean or median preoperative PSAV of patients with or without CAP who had undergone TURP or OP. Preoperative PSA decreased by 61.9%, 31.3%, and 92.9% postoperatively after TURP, HoLRP, and OP, respectively. The mean postoperative PSAVs for the year after intervention were 0.06, 0.06, and -0.13 for TURP, HoLRP, and OP, respectively. The mean postoperative PSAV for the men with CaP who underwent TURP and OP was 0.38 and 0.47, respectively, which were significantly greater than their BPH counterpart values. Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT Urology. 2009 May 8. Epub ahead of print. doi: 10.1016/j.urology.2008.10.062 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009